Sarepta Therapeutics (NasdaqGS:SRPT) reported positive three year functional results from its Phase 3 EMBARK trial of ...
ETHealthworld.com brings latest duchenne muscular dystrophy news, views and updates from all top sources for the Indian Health industry.
Sarepta Therapeutics (NASDAQ:SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ...
Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...
Surgical correction of scoliosis in patients with DMD remains controversial. This retrospective study enrolled patients who underwent posterior instrumented spinal fusion to correct spinal deformity ...
A retrospective cohort study found that, among 459 patients with DMD, constipation (32.5%) was the most common GI complication, followed by dysphagia (9.4%). Older age, lower body mass index, and use ...
Zacks Investment Research on MSN
SRPT stock up 8% on positive long-term data from Elevidys study in DMD
Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating ...
Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...
From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research. This year’s top stories on Duchenne muscular dystrophy (DMD) managed ...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results